Document Detail


Efficacy of intralesional bevacizumab injection in decreasing pterygium size.
MedLine Citation:
PMID:  20885313     Owner:  NLM     Status:  In-Process    
Abstract/OtherAbstract:
PURPOSE: To evaluate the efficacy of intralesional bevacizumab injection in decreasing size of pterygium.
METHODS: Seventeen patients with pterygium (14 with primary and 3 with recurrent pterygium) received intralesional injections of bevacizumab (2.5 mg/0.1 mL). Digital photographs were analyzed by image analysis software to determine the change of corneal involvement as a percentage of the total corneal surface.
RESULTS: The mean age of the patients was 45.5 ± 15.8 years. The mean percentage size of lesions before injection was 17.2% ± 4.3% of corneal surface. The mean percentage size of lesions 1 week, 1 month, and 3 months after injection was 15.1% ± 4.3%, 13.4% ± 4.0%, and 14.1% ± 4.4% of corneal surface, respectively. The mean percentage decrease of lesion size was 3.97% ± 3.84%. There were statistically significant differences between percentage of lesion size before and 1 week (P < 0.001), 1 month (P < 0.001), and 3 months (P < 0.001) after injection of bevacizumab. There were neither postinjection ocular complications such as rise of intraocular pressure nor systemic adverse events. Visual acuity did not change after injection of bevacizumab. Despite statistically significant decrease in pterygium size, this decrease does not seem to be clinically significant.
CONCLUSIONS: Intralesional bevacizumab injection is fairly effective in reducing the size of pterygium and is well tolerated; however, this effect is not clinically significant.
Authors:
Mohammad Reza Fallah Tafti; Keivan Khosravifard; Mehrdad Mohammadpour; Mohammad Naser Hashemian; Mohammad Yaser Kiarudi
Related Documents :
16939373 - Usability of a microtapered needle (tn3305) for insulin treatment in japanese patients ...
7837013 - Results of a prospective randomized trial of botulinum toxin therapy in acute unilatera...
7815243 - Effect of a medium dose of ursodeoxycholic acid with or without taurine supplementation...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Cornea     Volume:  30     ISSN:  1536-4798     ISO Abbreviation:  Cornea     Publication Date:  2011 Feb 
Date Detail:
Created Date:  2011-01-05     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8216186     Medline TA:  Cornea     Country:  United States    
Other Details:
Languages:  eng     Pagination:  127-9     Citation Subset:  IM    
Affiliation:
Eye Research Center, Farabi Eye Hospital, Cornea Department, Tehran University of Medical Sciences, Tehran, Iran. mahammadpour@yahoo.com
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Deep intrastromal bevacizumab injection for management of corneal stromal vascularization after deep...
Next Document:  Evaluation of central corneal thickness measurement with RTVue spectral domain optical coherence tom...